Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms the CirCe T-DM1 trial
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.